<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992377</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2021015</org_study_id>
    <nct_id>NCT04992377</nct_id>
  </id_info>
  <brief_title>R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL</brief_title>
  <acronym>BDHRT001</acronym>
  <official_title>A Multicenter Phase 2 Study of R-EPOCH in Combination With Ibrutinib for Patients With Classical Richter Transformation of Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xian-Janssen Pharmaceutical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated Phase 2 study, which combines R-EDOCH with Ibrutinib to&#xD;
      treat patients with Ritcher Transformation in consideration of DLBCL and CLL components both&#xD;
      could being targeted at the same time. The investigator will observe the 2-year overall&#xD;
      survival rate of this regimen for RT and explore the new regimen for RT in the novel drugs&#xD;
      era, which aims to improve the efficacy and prolong survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year overall survival rate (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time interval from enrollment to death of patients in the intent-to-treat population (ITT). If the patient is alive or death of the patient is unknown, the date of death will be the latest time point at which the patient was known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR)</measure>
    <time_frame>1 month after completion of consolidation therapy</time_frame>
    <description>Defined as the percentage of subjects who achieved CR after treatment in the per-protocol population as well as in the intent-to-treat population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>1 month after completion of consolidation therapy</time_frame>
    <description>Defined as the percentage of subjects who achieved CR + PR after treatment in the per-protocol population and the intention-to-treat population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time interval from enrollment to disease progression or death, whichever occurred first, for patients in the intent-to-treat (ITT) population. If there is no progression or time of disease progression is not recorded at the time of withdrawal from the trial, the date of the last examination will be used as the endpoint date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) negative rate</measure>
    <time_frame>1 month after completion of consolidation therapy</time_frame>
    <description>For patients with bone marrow invasion, on the basis of CR, multicolor flow cytometry detects that tumor cells account for the proportion of nuclear cells, and &lt; 0.01% are MRD negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxic side effects</measure>
    <time_frame>3 years</time_frame>
    <description>Non-hematologic toxicity was evaluated according to NCI CTCAE 5.0 criteria; hematologic toxicity was evaluated according to NCI CLL 2018 criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Richter Transformation</condition>
  <arm_group>
    <arm_group_label>R-EPOCH plus IBR for RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-EPOCH in Combination With Ibrutinib</intervention_name>
    <description>Induction:&#xD;
(21-day per cycle) Ibrutinib:420mg given orally , once daily.&#xD;
Details of R-DA-EPOCH are as follows:&#xD;
Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.&#xD;
Consolidation:&#xD;
2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment&#xD;
Maintenance:&#xD;
Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity</description>
    <arm_group_label>R-EPOCH plus IBR for RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years&#xD;
&#xD;
          2. ECOG 0-2&#xD;
&#xD;
          3. Confirmed Richter transformation, whether or not previously treated&#xD;
&#xD;
          4. Unexposed to BTKi, or discontinue BTKi more than 1 year (due not to toxicity or&#xD;
             ineffectiveness)&#xD;
&#xD;
          5. No serious liver, kidney, heart and other complications; including: a. alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit&#xD;
             of normal (ULN); b. total bilirubin (TBIL) ≤ 1.5 times the ULN; c. serum creatinine&#xD;
             (Cr) ≤ 2 times the ULN, or glomerular filtration rate ≥ 40ml/min; d. LVEF &gt; 50%&#xD;
             determined by echocardiography; e. no arrhythmia and active heart disease, such as&#xD;
             coronary heart disease, myocardial infarction, etc&#xD;
&#xD;
          6. The patient agreed to participate and signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major surgery within 4 weeks prior to first dose of ibrutinib&#xD;
&#xD;
          2. Require receiving anticoagulation with warfarin or equivalent Vitamin K antagonists;&#xD;
             Requires treatment with a strong CYP3A4/5 inhibitor&#xD;
&#xD;
          3. Require corticosteroid , anti-cancer drugs, immunomodulatory or Chinese medicine for&#xD;
             other medical conditions&#xD;
&#xD;
          4. Pregnant or lactating women&#xD;
&#xD;
          5. History of prior malignancy&#xD;
&#xD;
          6. Currently active clinically significant cardiovascular disease&#xD;
&#xD;
          7. Uncontrolled active systemic fungal, bacterial, viral, or other infection&#xD;
&#xD;
          8. Known history of human immunodeficiency virus (HIV) or active infection with Hepatitis&#xD;
             B or Hepatitis C&#xD;
&#xD;
          9. History of stroke or intracranial hemorrhage prior to randomization&#xD;
&#xD;
         10. Other conditions that is unfit for the clinical trial in the investigator' opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingyu Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tingyu Wang</last_name>
    <phone>+86 15692201678</phone>
    <email>wangtingyu@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuhua Yi</last_name>
    <phone>+86 15900265415</phone>
    <email>yishuhua@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking university Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongmei Jing</last_name>
      <email>Hongmei_jing@163.com</email>
    </contact>
    <investigator>
      <last_name>Hongmei Jing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second hospital of Hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinhai Ren</last_name>
      <email>Jinhai1966@sina.com</email>
    </contact>
    <investigator>
      <last_name>Jinhai Ren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lihong Liu</last_name>
      <email>13831177920@163.com</email>
    </contact>
    <investigator>
      <last_name>Lihong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Keshu Zhou</last_name>
      <email>drzhouks77@163.com</email>
    </contact>
    <investigator>
      <last_name>Keshu Keshu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second Xiangya hospital of central south university</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410012</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongling Peng</last_name>
      <phone>+86 13975806137</phone>
      <email>577769365@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hongling Peng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First affiliated hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fei Li</last_name>
      <phone>+86 13767186425</phone>
      <email>yx021021@sina.com</email>
    </contact>
    <investigator>
      <last_name>Fei Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ou Bai</last_name>
      <email>oubai16@163.com</email>
    </contact>
    <investigator>
      <last_name>Ou Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First affiliated hospital of China medical university</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110122</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaojing Yan</last_name>
      <email>yanxiaojing_pp@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiaojing Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250022</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zengjun Li</last_name>
      <phone>+86 13642138692</phone>
      <email>zengjunli@163.com</email>
    </contact>
    <investigator>
      <last_name>Zengjun Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030013</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liping Su</last_name>
      <email>sulp2015@163.com</email>
    </contact>
    <investigator>
      <last_name>Liping Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin university general hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jia Song</last_name>
      <phone>+86 13512055651</phone>
    </contact>
    <investigator>
      <last_name>Jia Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Tingyu Wang</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Richter transformation</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>R-EPOCH</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Therapeutics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

